Page last updated: 2024-09-05

sb 203580 and dicumarol

sb 203580 has been researched along with dicumarol in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (dicumarol)	Trials (dicumarol)	Recent Studies (post-2010) (dicumarol)
3,489	4	1,137	2,260	33	110

Protein Interaction Comparison

Protein	Taxonomy	dicumarol (IC50)
Cholinesterase	Homo sapiens (human)	0.0026
Cytochrome P450 2C9	Homo sapiens (human)	0.3
NAD	Homo sapiens (human)	0.2585
Mitogen-activated protein kinase 1	Homo sapiens (human)	4.426
Proprotein convertase subtilisin/kexin type 7	Homo sapiens (human)	1.3

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fennelly, C; Krause, D; Lyons, A; O'Connor, R	1
Belsey, MJ; Davies, AR; Kozlowski, RZ; Witchel, HJ	1

Other Studies

2 other study(ies) available for sb 203580 and dicumarol

Article	Year
Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol. The Journal of biological chemistry, 2001, Jun-01, Volume: 276, Issue:22 Topics: Anisomycin; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cytoskeleton; Dicumarol; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Interleukin-3; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Precipitin Tests; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Pyridines; Receptor, IGF Type 1; Recombinant Proteins; Time Factors; Transfection; Tumor Cells, Cultured; Tyrosine	2001
Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells. Neurochemical research, 2007, Volume: 32, Issue:11 Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Anthracenes; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dicumarol; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; Ion Channels; JNK Mitogen-Activated Protein Kinases; Necrosis; Niflumic Acid; Nitrobenzoates; Osmolar Concentration; Pyridines; Rats; Taurine	2007

Article

Year

Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol.

The Journal of biological chemistry, 2001, Jun-01, Volume: 276, Issue:22

Topics: Anisomycin; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cytoskeleton; Dicumarol; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Interleukin-3; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Precipitin Tests; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Pyridines; Receptor, IGF Type 1; Recombinant Proteins; Time Factors; Transfection; Tumor Cells, Cultured; Tyrosine

2001

Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells.

Neurochemical research, 2007, Volume: 32, Issue:11

Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Anthracenes; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dicumarol; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; Ion Channels; JNK Mitogen-Activated Protein Kinases; Necrosis; Niflumic Acid; Nitrobenzoates; Osmolar Concentration; Pyridines; Rats; Taurine

2007